McQueen Ball & Associates’s Madrigal Pharmaceuticals MDGL Stock Holding History

McQueen Ball & Associates’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,554	Closed	-$333K	–	116
2018 Q3	$333K	Hold	1,554	–	–	0.19%	81
2018 Q2	$435K	Sell	1,554 -1,000	-39%	-$176K	0.26%	77
2018 Q1	$298K	Buy	+2,554	New	+$315K	0.18%	87
2016 Q3	–	Sell	-2,935	Closed	-$27K	–	106
2016 Q2	$27K	Hold	2,935	–	–	0.02%	103
2016 Q1	$25K	Hold	2,935	–	–	0.02%	102
2015 Q4	$36K	Buy	+2,935	New	+$80.5K	0.03%	88

Other funds holding MDGL

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

McQueen Ball & Associates's MDGL Position: Q4 2018 in Review

McQueen Ball & Associates sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2018, closing a stake of 1,554 shares — an estimated $333K sold.

McQueen Ball & Associates first reported a position in MDGL in Q4 2015 and held it in 6 quarters. The position peaked at $435K in Q2 2018. 136 funds tracked by Wall St. Rank hold MDGL as of Q4 2018.

McQueen Ball & Associates reported no remaining Madrigal Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
McQueen Ball & Associates sold 1,554 Madrigal Pharmaceuticals shares in Q4 2018, an estimated $333K.
McQueen Ball & Associates first reported a position in Madrigal Pharmaceuticals in Q4 2015 and held it in 6 quarters.
McQueen Ball & Associates's Madrigal Pharmaceuticals position peaked at $435K in Q2 2018.
136 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2018.

Based on McQueen Ball & Associates's 13F filing for Q4 2018, filed 3 Jan 2019.